Literature DB >> 12070023

T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy.

Angela M Krackhardt1, Sabine Harig, Mathias Witzens, Ryan Broderick, Patrick Barrett, John G Gribben.   

Abstract

Chronic lymphocytic leukemia (CLL) cells are ineffective antigen-presenting cells (APCs) although CD40-activated CLL cells can stimulate proliferation of autologous and allogeneic T cells. We examined the antigen-presenting capacity of CD40-activated CLL cells as well as dendritic cells pulsed with apoptotic bodies of CLL cells to generate autologous and allogeneic immune responses against CLL cells. Both APC types were capable of generating T-cell lines that proliferate specifically in response to unstimulated CLL cells. Whereas cytotoxic responses against stimulated and unstimulated CLL cells could be repeatedly generated by allogeneic healthy donors, autologous cytotoxic immune responses against CD40-activated and native CLL cells were rarely detected. However, T cells isolated from patients with CLL could recognize and lyse allogeneic stimulated and unstimulated CLL cells, demonstrating that cytotoxic T cells from these tumor-bearing patients are functionally intact.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12070023     DOI: 10.1182/blood.v100.1.167

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status.

Authors:  Davorka Messmer; Gloria Telusma; Tarun Wasil; Bradley T Messmer; Steven Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2004 Jul-Dec       Impact factor: 6.354

2.  Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Authors:  Güllü Görgün; Tobias A W Holderried; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  J Clin Invest       Date:  2005-06-16       Impact factor: 14.808

3.  CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia.

Authors:  Mercedes Borge; Paula Romina Nannini; Jeremías Gastón Galletti; Pablo Elías Morande; Julio Sánchez Avalos; Raimundo Fernando Bezares; Mirta Giordano; Romina Gamberale
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 4.  Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug.

Authors:  Alan G Ramsay; John G Gribben
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

5.  Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells.

Authors:  K P Piper; M Karanth; A McLarnon; E Kalk; N Khan; J Murray; G Pratt; P A H Moss
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

6.  Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.

Authors:  Claudia Palena; Kenneth A Foon; Dennis Panicali; Alicia Gómez Yafal; Jarasvech Chinsangaram; James W Hodge; Jeffrey Schlom; Kwong Y Tsang
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

7.  Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.

Authors:  C Maurer; P Langerbeins; J Bahlo; P Cramer; A M Fink; N Pflug; A Engelke; J von Tresckow; G Kovacs; S Stilgenbauer; C-M Wendtner; L Müller; M Ritgen; T Seiler; K Fischer; M Hallek; B Eichhorst
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

8.  B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.

Authors:  Magdalena Hagn; Sue E Blackwell; Thamara Beyer; Verena Ebel; Dorit Fabricius; Stefanie Lindner; Stefan Stilgenbauer; Thomas Simmet; Constantine Tam; Paul Neeson; Joseph A Trapani; Hubert Schrezenmeier; George J Weiner; Bernd Jahrsdörfer
Journal:  Int Immunol       Date:  2014-02-04       Impact factor: 4.823

9.  Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.

Authors:  Scott Best; Vi Lam; Tingting Liu; Nur Bruss; Adam Kittai; Olga V Danilova; Susan Murray; Allison Berger; Nathan D Pennock; Evan F Lind; Alexey V Danilov
Journal:  Leukemia       Date:  2020-03-16       Impact factor: 11.528

10.  E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.

Authors:  Gullu Gorgun; Alan G Ramsay; Tobias A W Holderried; David Zahrieh; Rifca Le Dieu; Fenglong Liu; John Quackenbush; Carlo M Croce; John G Gribben
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.